论文部分内容阅读
目的探讨血清 β2 -微球蛋白 (β2 - M)对恶性实体瘤的诊断意义 方法放射免疫法 (RIA)测定 36例正常对照组和 190例各类恶性实体瘤患者的血清 β2 - M,并对结果进行统计分析。结果正常对照组血清 β2 - M为 (1.89± 0 .47) mg/ L,癌肿组为 (3.32± 0 .84) mg/ L,两者比较差异有显著性。以血清 β2 - M≥ 2 .9mg/ L 为阳性判断标准 ,癌肿组平均阳性率为 6 5 .8% ,肝癌、胰腺癌的阳性率最高 ,为 78.6 %和 77.8% ;乳腺癌阳性率最低 ,为 47.4%。结论血清 β2 - M对恶性实体瘤的诊断有一定价值 ,联合其他肿瘤标志物能提高检出阳性率 ,但要排除非肿瘤因素的干扰
Objective To investigate the significance of serum β2-microglobulin (β2-M) in the diagnosis of malignant solid tumors. Methods Radioimmunoassay (RIA) was used to measure serum β2-M in 36 normal controls and 190 patients with various types of malignant solid tumors. The results were statistically analyzed. Results The serum β2-M in the normal control group was (1.89±0.47) mg/L, and that in the cancer group was (3.32±0.84) mg/L. There was a significant difference between the two groups. Serum β2 - M ≥ 2.9 mg / L was the positive criterion. The average positive rate of cancer was 65.8%. The positive rates of liver cancer and pancreatic cancer were the highest, 78.6 % and 77.8%. The positive rate of breast cancer was the lowest. For 47.4%. Conclusion Serum β2 - M has a certain value in the diagnosis of malignant solid tumors, combined with other tumor markers can increase the positive rate of detection, but to exclude the interference of non-tumor factors